Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer entities : Veru inc. save search
Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer
Published: 2023-09-11 (Crawled : 11:00) - globenewswire.com
LLY | News | $731.81 -1.86% 1M
|
Health Technology
|
| O: 2.42%
H: 0.0%
C: 0.0%
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: 1.45%
H: 0.95%
C: 0.0%
breast cancer her2- study
Prostate Cancer Global Market to Witness Upsurge in Growth at a CAGR of ~5% by 2028 | DelveInsight
Published: 2023-07-05 (Crawled : 21:00) - prnewswire.com
ALPMY | News | $9.49 480K
|
Manufacturing
|
| O: 0.86%
H: 0.0%
C: -1.01%
NVS | News | $97.755 0.49% 1.1M
|
Health Technology
|
| O: -1.17%
H: 0.63%
C: 0.22%
LLY | News | $731.81 -1.86% 1M
|
Health Technology
|
| O: -0.55%
H: 0.97%
C: 0.02%
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: -6.72%
OPK | $1.225 -2.0% 3.5M
|
Health Technology
|
| O: -1.19%
H: 1.2%
C: -0.72%
ADXS | $0.54 950
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.83%
cancer global growth market
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published: 2022-06-06 (Crawled : 11:00) - globenewswire.com
LLY | News | $731.81 -1.86% 1M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: 10.2%
H: 0.0%
C: 0.0%
sabizabulin trial presentation positive cancer phase 2b prostate cancer
Veru/Lilly Aim to Fill Gap in Second-Line Metastatic Breast Cancer Therapy
Published: 2022-02-23 (Crawled : 14:00) - biospace.com/
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: 2.12%
H: 1.54%
C: -3.88%
therapy cancer breast cancer metastatic breast cancer
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
Published: 2022-02-17 (Crawled : 14:30) - biospace.com/
LLY | News | $731.81 -1.86% 1M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.88%
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: -0.96%
H: 0.88%
C: -3.38%
prostate cancer symposium state phase 1b presentation asco phase 1 cancer sabizabulin phase 2b
Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer
Published: 2021-12-08 (Crawled : 14:00) - biospace.com/
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: 0.39%
H: 7.82%
C: 5.63%
presentation preclinical cancer breast cancer pre-clinical metastatic breast cancer
Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium
Published: 2021-12-08 (Crawled : 13:30) - globenewswire.com
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: 0.39%
H: 7.82%
C: 5.63%
presentation preclinical cancer breast cancer pre-clinical symposium metastatic breast cancer
Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer
Published: 2021-10-13 (Crawled : 13:00) - globenewswire.com
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: 0.94%
H: 3.85%
C: 2.68%
test cancer phase 3 breast cancer trial enroll metastatic breast cancer
Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
Published: 2021-09-20 (Crawled : 13:15) - biospace.com/
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: -4.25%
H: 3.62%
C: -1.17%
GILD | $66.99 -0.06% 3.3M
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: 0.04%
prostate cancer phase 1 positive cancer phase 1b sabizabulin phase 2b
Veru Announces Oral Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
Published: 2021-09-09 (Crawled : 13:15) - biospace.com/
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: -1.31%
H: 5.75%
C: 3.73%
GILD | $66.99 -0.06% 3.3M
|
Health Technology
|
| O: -0.33%
H: 0.06%
C: -1.44%
presentation prostate cancer phase 1 cancer phase 1b sabizabulin phase 2b
Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 European Association of Urology Annual Congress
Published: 2021-06-28 (Crawled : 13:00) - globenewswire.com
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: 0.73%
H: 7.15%
C: 5.45%
presentation europe prostate cancer phase 1 cancer phase 1b sabizabulin phase 2b
Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer
Published: 2021-06-25 (Crawled : 13:00) - globenewswire.com
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: 1.46%
H: 0.96%
C: -1.8%
prostate cancer cancer phase 3 trial enroll sabizabulin
Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer
Published: 2021-06-10 (Crawled : 13:00) - globenewswire.com
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: -0.33%
H: 0.89%
C: -1.0%
treatment phase 2 prostate cancer injection cancer trial hormone enroll
Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 13:00) - globenewswire.com
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: 0.92%
H: 5.56%
C: 1.82%
phase 2 positive therapy cancer breast cancer her2+ her2- her2 metastatic breast cancer
Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021
Published: 2021-05-05 (Crawled : 13:00) - globenewswire.com
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: 20.23%
H: 6.88%
C: -15.97%
presentation phase 2 positive cancer breast cancer her2+ her2- her2 metastatic breast cancer
Veru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer Congress
Published: 2021-04-21 (Crawled : 13:00) - globenewswire.com
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: -0.79%
H: 5.11%
C: 4.88%
presentation phase 2 cancer breast cancer her2+ her2- her2
Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibitor Therapies
Published: 2021-01-19 (Crawled : 14:01) - globenewswire.com
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: 4.43%
H: 1.19%
C: -4.4%
positive endocrine cancer breast cancer hormone therapy metastatic breast cancer
Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer
Published: 2020-12-14 (Crawled : 13:01) - globenewswire.com
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: 55.31%
H: 9.73%
C: -1.77%
results breast cancer cancer positive endocrine trial trial results phase 2 metastatic breast cancer
VERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast Cancer
Published: 2020-12-14 (Crawled : 12:01) - globenewswire.com
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: 55.31%
H: 9.73%
C: -1.77%
breast cancer cancer preclinical pre-clinical
Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast Cancer
Published: 2020-12-09 (Crawled : 12:05) - globenewswire.com
VERU | $1.355 6.28% 910K
|
Health Technology
|
| O: 2.0%
H: 28.31%
C: 17.52%
breast cancer license cancer therapy endocrine drug phase 3 metastatic breast cancer
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $28.605 31.7% 9.9M
|
Finance
RBBN 4 | $3.305 28.6% 1.9M
|
Electronic Technology
RCAT | $1.53 27.5% 2.9M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.